TY - JOUR
T1 - Concurrent capecitabine and upper abdominal radiation therapy is well tolerated
AU - Das, Prajnan
AU - Wolff, Robert A.
AU - Abbruzzese, James L.
AU - Varadhachary, Gauri R.
AU - Evans, Douglas B.
AU - Vauthey, Jean Nicolas
AU - Baschnagel, Andrew
AU - Delclos, Marc E.
AU - Krishnan, Sunil
AU - Janjan, Nora A.
AU - Crane, Christopher H.
PY - 2006/10/24
Y1 - 2006/10/24
N2 - We retrospectively evaluated acute toxicity in 88 patients that were treated with capecitabine and concurrent radiotherapy to the upper abdomen. These patients included 28 (32%) with pancreatic adenocarcinoma, 18 (20%) with cholangiocarcinoma, 11 (13%) with ampullary carcinoma, 11 (13%) with other primary tumors, 14 (16%) with liver metastases, and 6 (7%) with metastases at other sites. The median dose of radiotherapy was 45 Gy (range 30-72 Gy). The median dose of capecitabine was 850 mg/m2 twice daily, with 77% receiving 800-900 mg/m2 twice daily. The highest grade of acute toxicity was Common Terminology Criteria (CTC) grade 0 in 5 (6%), grade 1 in 60 (68%), grade 2 in 18 (20%), and grade 3 in 5 (6%) patients. No patient had CTC grade 4 toxicity. The most common grade 2 toxicities were nausea, hand-foot syndrome, fatigue, anorexia and diarrhea. The grade 3 toxicities included nausea, vomiting and fatigue. Three patients (3%) required hospitalization due to grade 3 acute toxicity. Capecitabine was interrupted, discontinued or given at an adjusted dose in 13 (15%) patients because of acute toxicity. Therefore, capecitabine and concurrent radiotherapy to the upper abdomen appears to be well tolerated. Capecitabine may serve as an alternative to bolus or infusional 5-FU during chemoradiation for upper gastrointestinal malignancies.
AB - We retrospectively evaluated acute toxicity in 88 patients that were treated with capecitabine and concurrent radiotherapy to the upper abdomen. These patients included 28 (32%) with pancreatic adenocarcinoma, 18 (20%) with cholangiocarcinoma, 11 (13%) with ampullary carcinoma, 11 (13%) with other primary tumors, 14 (16%) with liver metastases, and 6 (7%) with metastases at other sites. The median dose of radiotherapy was 45 Gy (range 30-72 Gy). The median dose of capecitabine was 850 mg/m2 twice daily, with 77% receiving 800-900 mg/m2 twice daily. The highest grade of acute toxicity was Common Terminology Criteria (CTC) grade 0 in 5 (6%), grade 1 in 60 (68%), grade 2 in 18 (20%), and grade 3 in 5 (6%) patients. No patient had CTC grade 4 toxicity. The most common grade 2 toxicities were nausea, hand-foot syndrome, fatigue, anorexia and diarrhea. The grade 3 toxicities included nausea, vomiting and fatigue. Three patients (3%) required hospitalization due to grade 3 acute toxicity. Capecitabine was interrupted, discontinued or given at an adjusted dose in 13 (15%) patients because of acute toxicity. Therefore, capecitabine and concurrent radiotherapy to the upper abdomen appears to be well tolerated. Capecitabine may serve as an alternative to bolus or infusional 5-FU during chemoradiation for upper gastrointestinal malignancies.
UR - http://www.scopus.com/inward/record.url?scp=34248392299&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34248392299&partnerID=8YFLogxK
U2 - 10.1186/1748-717X-1-41
DO - 10.1186/1748-717X-1-41
M3 - Article
C2 - 17062148
AN - SCOPUS:34248392299
SN - 1748-717X
VL - 1
JO - Radiation Oncology
JF - Radiation Oncology
IS - 1
M1 - 41
ER -